http://orcid.org/0000-0003-3448-5555
References
- Dalia Y, Johnson S. Case report: first reported case of facial rash after dupilumab therapy. Pract Dermatol. 2018;25–26.
- Shirley M. Dupilumab: first global approval. Drugs. 2017;77:1115–1121.
- Smogorzewski J, Sierro T, Compoginis G, et al. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019;5:116–117.
- Salgüero-Fernández I, Gonzalez de DM, Suarez D, Roustan-Gullón G. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol. 2019;44:e41–e43.
- Hendricks AJ, Lio PA, Shi VY. Dupilumab and alopecia: causative or therapeutic? Dermatology. 2019;18:1–2.
- Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019;44:e49–50.
- Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018;4:708–710.
- Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep. 2018;4:899–904.
- Collantes-Rodríguez C, Jiménez-Gallo D, Ossorio-García L, et al. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. Contact Derm. 2019;80:69–70.
- Penzi LR, Yasuda M, Manatis-Lornell A, et al. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154:1358–1360.
- Treatment of Alopecia Areata (AA) with dupilumab in patients with and without Atopic Dermatitis (AD) – Full Text View – ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine,
- Ahn CS, Huang WW. Rosacea pathogenesis. Dermatol Clin. 2018;36:81–86. 04
- Reinholz M, Ruzicka T, Steinhoff M, et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Ges. 2016;14:4–15.
- Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327–341.
- Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178:1220.
- Tisma VS, Basta-Juzbasić A, Dobrić I, et al. Etiopathogenesis, classification, and current trends in treatment of rosacea. Acta Dermatovenerol Croat. 2003;11:236–246.
- Falay Gur T, Erdemir AV, Gurel MS, et al. The investigation of the relationships of demodex density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res. 2018;310:759–767.
- Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 Pathways. J Invest Dermatol. 2015;135:2198–2208.
- Kim JT, Lee SH, Chun YS, et al. Tear cytokines and chemokines in patients with demodex blepharitis. Cytokine. 2011;53:94–99.
- Maarouf M, Saberian C, Lio PA, et al. Dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol. 2018;35:748–753.
- Shi V, Hendricks A. Head-and-neck atopic dermatitis. The Dermatologist [Internet]. 2019. Available from: https://www.the-dermatologist.com/article/head-and-neck-atopic-dermatitis